News

PRAC February 2026 – PRAC recommends the withdrawal of medicines containing levamisole

During its February 2026 meeting, the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency recommended the withdrawal of medicines containing levamisole from the EU market. These medicinal products are not marketed in Belgium, but are included in the World Health Organisation list of essential medicines.

Give your opinion on a genetically modified medicine against Amyotrophic Lateral Sclerosis

The FPS Public Health and the FAMHP invite you to participate in the public consultation on a clinical trial of the genetically modified medicine VTx-002 for the treatment of Amyotrophic Lateral Sclerosis (ALS). The public consultation will take place from February 9th to March 11th, 2026.

Risk of overdose with oral methotrexate: reminder of recommendations for the treatment of inflammatory diseases

Oral methotrexate can cause serious side effects in the event of overdose. Despite the measures put in place, cases of accidental overdose continue to be reported. Most cases result from taking the medicine too often compared to the prescription. For the treatment of inflammatory diseases, oral methotrexate should only be taken once a week, always on the same day.